Indications and uses
lightens dark (brownish) discoloration in the skin such as age and liver spots
lightens dark (brownish) discoloration in the skin such as age and liver spots
adults: brush a small amount twice daily. Rub in. limit sun exposure and use a sunscreen, a sun blocking agent or protective clothing to cover bleached skin when using and after using this product in order to prevent darkening from reoccurring discontinue if symptoms persist for more than 3 months children under 12 years of age, consult a doctor before use
store at 15º to 30ºC (59 to 86ºF) keep bottle tightly closed or product will evaporate
Hydroquinone 2%
Skin Lightener
For external use only
If swallowed, get medical help or contact a Poison Control Center right away.
retinoic acid, melatonin, MSM, BHT, na metabisulfite, arbutin, cystamine, licorice root, dandelion root, hydroxyanisole, ascorbic acid, hydroxypropylcellulose, kojic acid, azelaic acid, acetone, propylene glycol, ethyl alcohol (SDA), distilled water q.s.
call
1-877-566-5935| Class | Version | Type | Effective |
|---|---|---|---|
| HYDROQUINONE Pharmacologic Class Indexing | 2 | Indexing - Pharmacologic Class | 20180813 |
| Product concept | Relation | Version | Effective |
|---|---|---|---|
| b80ad7bc-1b6f-7ef4-1ed0-86cd9f459d60 | Product name | 6 | 20251124 |
| 1426d8f8-b7d5-4053-8554-613df00c0d86 | Product name | 2 | 20250616 |
| 0e7b8bf1-c46c-4de6-b26a-0c50e34364ec | Product name | 2 | 20250521 |
| e3af9708-3004-7392-4046-5311eaa8bab5 | Product name | 3 | 20221128 |
| 13e7e7e3-e885-4c79-af6d-dad1aedbb06e | Product name | 1 | 20220128 |
| 6c6fc281-9445-2e9e-1c29-a09ddbc4299c | Product name | 2 | 20200213 |
| 503b047e-e62d-4745-9011-522b13bc701b | Product name | 1 | 20181206 |
| 7d41caa2-0b5d-9b03-ab8d-84271de26ef4 | Product name | 2 | 20170314 |
| 50ca9ff5-82dd-9971-4f2c-5845a76a8572 | Product name | 2 | 20150818 |
| 2a856070-cbe7-4f85-be0f-09885ff91196 | Product name | 1 | 20150806 |
| 0a8118e4-08c6-b395-9ddc-d3e425e0493a | Product name | 1 | 20140508 |
| 233bcb0a-cf40-b0a1-b346-c83ac2f43579 | Product name | 1 | 20140508 |
| 85490a6b-2306-6bf2-c51b-eb63537dc2da | Product name | 1 | 20140508 |
| NDC | Effective | Action | Document | Indexing SPL | Related label |
|---|---|---|---|---|---|
| 64269-9902-7 | 2020-01-31 | C162847 | 48780-1 | 9d75b9d1-0c5d-f424-e053-dadaa90a57ce | Drug Facts |
| 64269-9902-8 | 2020-01-31 | C162847 | 48780-1 | 9d75b9d1-0c5d-f424-e053-dadaa90a57ce | Drug Facts |
| Package NDC | Product | Description | Form | Quantity | Strength | SPL version |
|---|---|---|---|---|---|---|
| 64269-9902-7 | Scarlight MD | 15 mL in 1 BOTTLE, WITH APPLICATOR | LIQUID | 15 | 1 | |
| 64269-9902-8 | Scarlight MD | 30 mL in 1 BOTTLE, WITH APPLICATOR | LIQUID | 30 | 1 |
| NDC | Dashboard title | SPL version | Validation | Dashboard ZIP |
|---|---|---|---|---|
| 64269-9902 | SCARLIGHT MD (HYDROQUINONE) LIQUID [SCARGUARD LABS, LLC] | 1 | Legacy NDC, 2 package rows | 20091230_c24a9fd8-1fb5-4643-92df-b268479a35e5.zip |
| Ingredient | Type | UNII | SPL version | Uploaded |
|---|---|---|---|---|
| HYDROQUINONE | ACTIVE INGREDIENT | XV74C1N1AE | 1 | |
| Hydroquinone | ACTIVE MOIETY | XV74C1N1AE | 1 | |
| Acetone | INACTIVE INGREDIENT | 1364PS73AF | 1 | |
| Alcohol | INACTIVE INGREDIENT | 3K9958V90M | 1 | |
| Arbutin | INACTIVE INGREDIENT | C5INA23HXF | 1 | |
| Ascorbic Acid | INACTIVE INGREDIENT | PQ6CK8PD0R | 1 | |
| Azelaic Acid | INACTIVE INGREDIENT | F2VW3D43YT | 1 | |
| Butylated Hydroxyanisole | INACTIVE INGREDIENT | REK4960K2U | 1 | |
| Butylated Hydroxytoluene | INACTIVE INGREDIENT | 1P9D0Z171K | 1 | |
| Cystamine | INACTIVE INGREDIENT | R110LV8L02 | 1 | |
| Dimethyl Sulfone | INACTIVE INGREDIENT | 9H4PO4Z4FT | 1 | |
| Hydroxypropyl Cellulose | INACTIVE INGREDIENT | RFW2ET671P | 1 | |
| Kojic Acid | INACTIVE INGREDIENT | 6K23F1TT52 | 1 | |
| Licorice | INACTIVE INGREDIENT | 61ZBX54883 | 1 | |
| Melatonin | INACTIVE INGREDIENT | JL5DK93RCL | 1 | |
| Propylene Glycol | INACTIVE INGREDIENT | 6DC9Q167V3 | 1 | |
| Sodium Metabisulfite | INACTIVE INGREDIENT | 4VON5FNS3C | 1 | |
| TARAXACUM OFFICINALE ROOT | INACTIVE INGREDIENT | 9DE5YCO0RU | 1 | |
| Tretinoin | INACTIVE INGREDIENT | 5688UTC01R | 1 | |
| Water | INACTIVE INGREDIENT | 059QF0KO0R | 1 |
Every source-derived product name is available through these pages.
| Product NDC | Package NDC |
|---|---|
| 64269-9902 | 64269-9902-8, 64269-9902-7 |
Every source-derived ingredient row is available through these pages.
Inactive Ingredient Database values describe FDA-listed use contexts. The match method and ambiguity count are shown because ingredient names, routes, and dosage forms are not always unique. Browse recovered IID releases and source provenance.
| DailyMed ingredient | IID ingredient | UNII | Dosage form / route | Potency | Maximum daily exposure | Match |
|---|---|---|---|---|---|---|
| Sodium Metabisulfite | SODIUM METABISULFITE | 4VON5FNS3C | INJECTION, SOLUTION, CONCENTRATE / SUBCUTANEOUS | 0.15 %w/v | ||
| Ascorbic Acid | ASCORBIC ACID | PQ6CK8PD0R | TABLET, ORALLY DISINTEGRATING / ORAL | 2.35 mg | ||
| Propylene Glycol | PROPYLENE GLYCOL | 6DC9Q167V3 | DROPS / ORAL | 200 mg/1ml | ||
| Butylated Hydroxytoluene | BUTYLATED HYDROXYTOLUENE | 1P9D0Z171K | FILM, SOLUBLE / ORAL | 0.06 mg | ||
| Alcohol | ALCOHOL | 3K9958V90M | LIQUID / ORAL | 3563 mg | ||
| Propylene Glycol | PROPYLENE GLYCOL | 6DC9Q167V3 | TABLET, COATED / ORAL | 16 mg | ||
| Propylene Glycol | PROPYLENE GLYCOL | 6DC9Q167V3 | FILM, SOLUBLE / BUCCAL | 5 mg | ||
| Propylene Glycol | PROPYLENE GLYCOL | 6DC9Q167V3 | CREAM / TOPICAL | 76000 mg | ||
| Alcohol | ALCOHOL | 3K9958V90M | AEROSOL, METERED / RESPIRATORY (INHALATION) | 26664 mg | ||
| Propylene Glycol | PROPYLENE GLYCOL | 6DC9Q167V3 | OINTMENT, AUGMENTED / TOPICAL | 714 mg | ||
| Ascorbic Acid | ASCORBIC ACID | PQ6CK8PD0R | CAPSULE / ORAL | 7 mg | ||
| Butylated Hydroxytoluene | BUTYLATED HYDROXYTOLUENE | 1P9D0Z171K | INJECTION, SOLUTION / INTRAVENOUS | NA | ||
| Butylated Hydroxytoluene | BUTYLATED HYDROXYTOLUENE | 1P9D0Z171K | CREAM / VAGINAL | 0.05 %w/w | ||
| Propylene Glycol | PROPYLENE GLYCOL | 6DC9Q167V3 | SOLUTION/ DROPS / AURICULAR (OTIC) | ADJ PH | ||
| Butylated Hydroxyanisole | BUTYLATED HYDROXYANISOLE | REK4960K2U | CAPSULE, LIQUID FILLED / ORAL | 4 mg | ||
| Sodium Metabisulfite | SODIUM METABISULFITE | 4VON5FNS3C | SUSPENSION / TOPICAL | 0.32 %w/v | ||
| Propylene Glycol | PROPYLENE GLYCOL | 6DC9Q167V3 | SOLUTION, CONCENTRATE / INTRAVENOUS | 50.33 %w/v | ||
| Butylated Hydroxyanisole | BUTYLATED HYDROXYANISOLE | REK4960K2U | SYRUP / ORAL | 1 mg | ||
| Ascorbic Acid | ASCORBIC ACID | PQ6CK8PD0R | SUSPENSION, EXTENDED RELEASE / ORAL | 6 mg | ||
| Sodium Metabisulfite | SODIUM METABISULFITE | 4VON5FNS3C | INJECTION / SUBMUCOSAL | 5 mg | ||
| Hydroxypropyl Cellulose | HYDROXYPROPYL CELLULOSE (1600000 WAMW) | RFW2ET671P | LOTION, AUGMENTED / TOPICAL | 0.2 %w/w | ||
| Sodium Metabisulfite | SODIUM METABISULFITE | 4VON5FNS3C | INJECTION / INTRACARDIAC | 0.09 %w/v | ||
| Propylene Glycol | PROPYLENE GLYCOL | 6DC9Q167V3 | SOLUTION / TOPICAL | 4886 mg | ||
| Butylated Hydroxyanisole | BUTYLATED HYDROXYANISOLE | REK4960K2U | INJECTION / INTRAVENOUS | NA | ||
| Propylene Glycol | PROPYLENE GLYCOL | 6DC9Q167V3 | SUSPENSION / TOPICAL | 5.28 %w/v | ||
| Propylene Glycol | PROPYLENE GLYCOL | 6DC9Q167V3 | EMULSION / TOPICAL | 8 %w/w | ||
| Propylene Glycol | PROPYLENE GLYCOL | 6DC9Q167V3 | SUSPENSION / RECTAL | 90400 mg | ||
| Ascorbic Acid | ASCORBIC ACID | PQ6CK8PD0R | SUPPOSITORY / RECTAL | 3 mg | ||
| Propylene Glycol | PROPYLENE GLYCOL | 6DC9Q167V3 | SUSPENSION, EXTENDED RELEASE / ORAL | 1000 mg | ||
| Hydroxypropyl Cellulose | HYDROXYPROPYL CELLULOSE (1600000 WAMW) | RFW2ET671P | TABLET, DELAYED RELEASE / ORAL | 450 mg | ||
| Propylene Glycol | PROPYLENE GLYCOL | 6DC9Q167V3 | SUSPENSION / AURICULAR (OTIC) | 10 %w/v | ||
| Butylated Hydroxytoluene | BUTYLATED HYDROXYTOLUENE | 1P9D0Z171K | TABLET / SUBLINGUAL | 0.13 mg | ||
| Sodium Metabisulfite | SODIUM METABISULFITE | 4VON5FNS3C | INJECTION / EPIDURAL | 0.05 %w/v | ||
| Ascorbic Acid | ASCORBIC ACID | PQ6CK8PD0R | INJECTION, POWDER, FOR SOLUTION / INTRAVENOUS | 2 mg | ||
| Propylene Glycol | PROPYLENE GLYCOL | 6DC9Q167V3 | SOLUTION, CONCENTRATE / ORAL | 2590 mg | ||
| Butylated Hydroxyanisole | BUTYLATED HYDROXYANISOLE | REK4960K2U | CAPSULE / ORAL | 4 mg | ||
| Sodium Metabisulfite | SODIUM METABISULFITE | 4VON5FNS3C | SUSPENSION, EXTENDED RELEASE / ORAL | 100 mg | ||
| Alcohol | ALCOHOL | 3K9958V90M | SOLUTION / TRANSDERMAL | 49.37 %w/v | ||
| Sodium Metabisulfite | SODIUM METABISULFITE | 4VON5FNS3C | TABLET / ORAL | 8 mg | ||
| Sodium Metabisulfite | SODIUM METABISULFITE | 4VON5FNS3C | INJECTION, SOLUTION / SUBCUTANEOUS | 79 mg | ||
| Alcohol | ALCOHOL | 3K9958V90M | SOLUTION, CONCENTRATE / INTRAVENOUS | 4000 mg | ||
| Butylated Hydroxytoluene | BUTYLATED HYDROXYTOLUENE | 1P9D0Z171K | LOTION / TOPICAL | 1000 mg | ||
| Butylated Hydroxytoluene | BUTYLATED HYDROXYTOLUENE | 1P9D0Z171K | SOAP / TOPICAL | 0.02 %w/w | ||
| Propylene Glycol | PROPYLENE GLYCOL | 6DC9Q167V3 | SHAMPOO / TOPICAL | 8 %w/w | ||
| Alcohol | ALCOHOL | 3K9958V90M | SUSPENSION / RECTAL | 0.35 %v/v | ||
| Propylene Glycol | PROPYLENE GLYCOL | 6DC9Q167V3 | INJECTION / SUBCUTANEOUS | 1.4 %w/v | ||
| Alcohol | ALCOHOL | 3K9958V90M | AEROSOL, SPRAY / RESPIRATORY (INHALATION) | 35.75 %w/w | ||
| Propylene Glycol | PROPYLENE GLYCOL | 6DC9Q167V3 | GEL / TOPICAL | 4522 mg | ||
| Propylene Glycol | PROPYLENE GLYCOL | 6DC9Q167V3 | SOLUTION / RESPIRATORY (INHALATION) | 25 %w/w | ||
| Hydroxypropyl Cellulose | HYDROXYPROPYL CELLULOSE (1600000 WAMW) | RFW2ET671P | SUSPENSION / ORAL | 100 mg | ||
| Sodium Metabisulfite | SODIUM METABISULFITE | 4VON5FNS3C | SYRUP / ORAL | 80 mg | ||
| Propylene Glycol | PROPYLENE GLYCOL | 6DC9Q167V3 | FILM, EXTENDED RELEASE / TRANSDERMAL | 58.13 mg | ||
| Alcohol | ALCOHOL | 3K9958V90M | CONCENTRATE / ORAL | 198 mg | ||
| Ascorbic Acid | ASCORBIC ACID | PQ6CK8PD0R | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION / INTRAVENOUS | 1440 mg | ||
| Butylated Hydroxytoluene | BUTYLATED HYDROXYTOLUENE | 1P9D0Z171K | GEL / TOPICAL | 8 mg | ||
| Alcohol | ALCOHOL | 3K9958V90M | SOLUTION / ORAL | 6624 mg | ||
| Butylated Hydroxyanisole | BUTYLATED HYDROXYANISOLE | REK4960K2U | LOTION / TOPICAL | NA | ||
| Sodium Metabisulfite | SODIUM METABISULFITE | 4VON5FNS3C | SUSPENSION / ORAL | 40 mg | ||
| Ascorbic Acid | ASCORBIC ACID | PQ6CK8PD0R | AEROSOL, METERED / RESPIRATORY (INHALATION) | 0.1 %w/w | ||
| Alcohol | ALCOHOL | 3K9958V90M | GEL / DENTAL | 1.8 %w/w |
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| ad6d99fb-9b13-47d5-b0ed-b2312b2b1274 | c24a9fd8-1fb5-4643-92df-b268479a35e5 | 2009-12-29 | Warnings | ad6d99fb-9b13-47d5-b0ed-b2312b2b1274 c24a9fd8-1fb5-4643-92df-b268479a35e5 |
Adverse event summaries are temporarily unavailable. Other product information remains available.